A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors
Apollo Therapeutics Ltd
Summary
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * 18 years or older * Phase 1: Histologically confirmed locally advanced, inoperable, or metastatic tumor; Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma. * For Phase 1 sub-studies: Colorectal carcinoma, Cholangiocarcinoma, Appendiceal adenocarcinoma, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Endometrial Adenocarcinoma, Triple Negative Breast Cancer, Ovarian Cancer, Prostate Cancer * Phase 2: Colorectal carcinoma * No available standard of care therapy or participant is ineligible for standard of care therapy, except in CRC tumor type in whic…
Interventions
- DrugAPL-5125
APL-5125 is an oral drug (capsule) taken daily in 28-day cycles
Locations (9)
- City of HopeDuarte, California
- City of Hope Orange County Lennar Foundation Cancer CenterIrvine, California
- Florida Cancer Specialists & Research InstituteSarasota, Florida
- University of MichiganAnn Arbor, Michigan
- Duke Cancer InstituteDurham, North Carolina
- Carolina BioOncology InstituteHuntersville, North Carolina